{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:24:18Z","timestamp":1785414258608,"version":"3.56.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The management of metastatic castration-resistant prostate cancer (mCRPC) following progression on androgen deprivation therapy (ADT) combined with androgen receptor pathway inhibitors (ARPI) in the castration-sensitive (CS) setting remains unclear. Limited data exist comparing the efficacy of ARPI versus docetaxel as first-line treatment in this context.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective multicentre study across three tertiary cancer centres in Saudi Arabia, including 60 patients with pathologically confirmed mCRPC who progressed after doublet therapy (ADT\u2009+\u2009ARPI) in the CS setting between January 2018 and September 2022. Patients received either ARPI (abiraterone acetate or enzalutamide) or docetaxel as first-line therapy for mCRPC. Primary endpoints were prostate-specific antigen (PSA) response rate and biochemical progression-free survival (PFS). Secondary endpoints included overall survival (OS) and treatment patterns. PSA response was defined as \u2265\u200930% decline at 12 weeks from baseline. Survival analyses were performed using Kaplan-Meier and log-rank tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 60 eligible patients (median age 65 years), 28 received ARPI and 32 received docetaxel. PSA response rates were 39.3% for ARPI and 37.5% for docetaxel. Median PFS was 2.9 months (95% CI 0.37\u20135.5) for ARPI and 4.5 months (95% CI 2.6\u20136.3) for docetaxel (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.137). Median OS was 13 months (95% CI 4.0\u201323.9) for ARPI and 16 months (95% CI 6.1\u201325.9) for docetaxel (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.236). In patients with visceral metastases, docetaxel conferred significantly longer OS compared to ARPI (14.4 vs. 5.9 months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.025). Multivariate analysis identified nadir PSA in the CS setting as a predictor of PFS and first-line therapy in the CR setting, visceral metastasis and duration of therapy in CS setting as predictors of OS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients progressing to mCRPC after doublet therapy in the CS setting, docetaxel demonstrated a trend toward longer PFS and OS compared to ARPI, with a significant survival advantage in those with visceral metastases. These findings highlight the need for prospective randomized trials and biomarker-driven treatment strategies to optimize therapy sequencing in this evolving treatment landscape.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12894-025-02019-8","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T04:33:48Z","timestamp":1766378028000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Docetaxel versus androgen receptor pathway inhibitors as first-line therapy for metastatic castration-resistant prostate cancer after doublet therapy: a multicenter retrospective study from Saudi Arabia"],"prefix":"10.1186","volume":"25","author":[{"given":"Shouki","family":"Bazarbashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed S.","family":"Abdelmotal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Arabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Fallatah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noura","family":"Alzannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tusneem","family":"Elhassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Aseafan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Mahroos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maram","family":"Aljishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albatool","family":"Busbaih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajaa","family":"Aldandan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shahzad","family":"Rauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad A","family":"Almugbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Azam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mubarak","family":"Almansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"issue":"8970","key":"2019_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0140-6736(95)92163-X","volume":"346","author":"Maximum androgen blockade in advanced","year":"1995","unstructured":"Maximum androgen blockade in advanced. Prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate cancer trialists\u2019 collaborative group. Lancet. 1995;346(8970):265\u20139.","journal-title":"Lancet"},{"issue":"15","key":"2019_CR2","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or Mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502\u201312.","journal-title":"N Engl J Med"},{"issue":"21","key":"2019_CR3","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995\u20132005.","journal-title":"N Engl J Med"},{"issue":"5","key":"2019_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424\u201333.","journal-title":"N Engl J Med"},{"issue":"3","key":"2019_CR5","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/j.clgc.2014.12.004","volume":"13","author":"RR Aggarwal","year":"2015","unstructured":"Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, et al. Intermittent chemotherapy as a platform for testing novel agents in patients with metastatic Castration-Resistant prostate cancer: A department of defense prostate cancer clinical trials consortium randomized phase II trial of intermittent docetaxel with prednisone with or without maintenance GM-CSF. Clin Genitourin Cancer. 2015;13(3):e191\u20138.","journal-title":"Clin Genitourin Cancer"},{"issue":"25","key":"2019_CR6","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1200\/JCO.2018.77.9827","volume":"36","author":"G Attard","year":"2018","unstructured":"Attard G, Borre M, Gurney H, Loriot Y, Andresen-Daniil C, Kalleda R, et al. Abiraterone alone or in combination with enzalutamide in metastatic Castration-Resistant prostate cancer with rising prostate-Specific antigen during enzalutamide treatment. J Clin Oncol. 2018;36(25):2639\u201346.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.eururo.2014.06.045","volume":"67","author":"AA Azad","year":"2015","unstructured":"Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol. 2015;67(1):23\u20139.","journal-title":"Eur Urol"},{"key":"2019_CR8","doi-asserted-by":"publisher","unstructured":"Azad A, Lester R, Heng YC, Eigl BJ. Chi\u00a0KN. Impact of prior response to abiraterone acetate (AA) on subsequent activity of docetaxel (D) in metastatic castrationresistant prostate cancer American society for clinical oncology. J Clin Oncol. 2014;32(4):97. https:\/\/doi.org\/10.1200\/jco.2014.32.4_suppl.97.","DOI":"10.1200\/jco.2014.32.4_suppl.97"},{"issue":"4","key":"2019_CR9","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.eururo.2016.08.012","volume":"71","author":"M Del Re","year":"2017","unstructured":"Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini C, et al. The detection of androgen receptor splice variant 7 in Plasma-derived Exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients. Eur Urol. 2017;71(4):680\u20137.","journal-title":"Eur Urol"},{"issue":"11","key":"2019_CR10","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1093\/annonc\/mds119","volume":"23","author":"J Mezynski","year":"2012","unstructured":"Mezynski J, Pezaro C, Bianchini D, Zivi A, Sandhu S, Thompson E, et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol. 2012;23(11):2943\u20137.","journal-title":"Ann Oncol"},{"issue":"4","key":"2019_CR11","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.clgc.2015.01.004","volume":"13","author":"T Zhang","year":"2015","unstructured":"Zhang T, Dhawan MS, Healy P, George DJ, Harrison MR, Oldan J, et al. Exploring the clinical benefit of docetaxel or enzalutamide after disease progression during abiraterone acetate and prednisone treatment in men with metastatic Castration-Resistant prostate cancer. Clin Genitourin Cancer. 2015;13(4):392\u20139.","journal-title":"Clin Genitourin Cancer"},{"issue":"10459","key":"2019_CR12","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, et al. Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404(10459):1227\u201339.","journal-title":"Lancet"},{"issue":"26","key":"2019_CR13","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","volume":"381","author":"R de Wit","year":"2019","unstructured":"de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, W\u00fclfing C, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381(26):2506\u201318.","journal-title":"N Engl J Med"},{"issue":"8","key":"2019_CR14","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, et al. Rucaparib or physician\u2019s choice in metastatic prostate cancer. N Engl J Med. 2023;388(8):719\u201332.","journal-title":"N Engl J Med"},{"key":"2019_CR15","doi-asserted-by":"publisher","first-page":"1378993","DOI":"10.3389\/fonc.2024.1378993","volume":"14","author":"D Zhang","year":"2024","unstructured":"Zhang D, Weng H, Zhu Z, Gong W, Ma Y. Evaluating first-line therapeutic strategies for metastatic castration-resistant prostate cancer: a comprehensive network meta-analysis and systematic review. Front Oncol. 2024;14:1378993.","journal-title":"Front Oncol"},{"issue":"1","key":"2019_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00345-024-05388-1","volume":"43","author":"M Wenzel","year":"2024","unstructured":"Wenzel M, Hoeh B, Humke C, Cano Garcia C, Siech C, Steuber T, et al. Androgen receptor pathway inhibitors vs. docetaxel chemotherapy for metastatic hormone-sensitive and first-line castration resistant prostate cancer. World J Urol. 2024;43(1):51.","journal-title":"World J Urol"},{"issue":"11","key":"2019_CR17","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1038\/s41591-024-03204-2","volume":"30","author":"B De Laere","year":"2024","unstructured":"De Laere B, Crippa A, Discacciati A, Larsson B, Persson M, Johansson S, et al. Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial. Nat Med. 2024;30(11):3291\u2013302.","journal-title":"Nat Med"},{"key":"2019_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/cancers13194951","volume":"13","author":"U Swami","year":"2021","unstructured":"Swami U, Sinnott JA, Haaland B, Sayegh N, McFarland TR, Tripathi N, et al. Treatment pattern and outcomes with systemic therapy in men with metastatic prostate cancer in the Real-World patients in the united States. Cancers (Basel). 2021;13:19.","journal-title":"Cancers (Basel)"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-02019-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-02019-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-02019-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T20:40:21Z","timestamp":1767040821000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12894-025-02019-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2019"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-02019-8","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was by the research ethics committee at King Faisal Specialist Hospital & Research Centre RAC #2231036 on 20 Feb 2023 and by the Ethics Committee of all other participating centres.The Ethics Committee granted this study a waiver of consent due to the retrospective nature of study by the research ethics committee at King Faisal Specialist Hospital & Research Centre RAC #2231036 on 20 Feb 2023 and by the Ethics Committee of all other participating centres.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"306"}}